nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—IRAK1—IL1 and megakaryotyces in obesity—TIMP2—intracranial aneurysm	0.0497	0.0848	CbGpPWpGaD
Gefitinib—CHEK2—ATM pathway—RBBP8—intracranial aneurysm	0.0467	0.0797	CbGpPWpGaD
Gefitinib—EGFR—EGFR-dependent Endothelin signaling events—EDNRA—intracranial aneurysm	0.0246	0.0421	CbGpPWpGaD
Gefitinib—SBK1—medulla oblongata—intracranial aneurysm	0.023	0.0555	CbGeAlD
Gefitinib—SBK1—midbrain—intracranial aneurysm	0.021	0.0507	CbGeAlD
Gefitinib—IRAK1—IL1 and megakaryotyces in obesity—TIMP1—intracranial aneurysm	0.0164	0.028	CbGpPWpGaD
Gefitinib—SBK1—cerebellum—intracranial aneurysm	0.0162	0.0392	CbGeAlD
Gefitinib—SBK1—brain—intracranial aneurysm	0.0132	0.0319	CbGeAlD
Gefitinib—HIPK4—brain—intracranial aneurysm	0.013	0.0315	CbGeAlD
Gefitinib—CSNK1E—medulla oblongata—intracranial aneurysm	0.0127	0.0306	CbGeAlD
Gefitinib—IRAK4—medulla oblongata—intracranial aneurysm	0.0125	0.0302	CbGeAlD
Gefitinib—MAP2K5—brainstem—intracranial aneurysm	0.0121	0.0293	CbGeAlD
Gefitinib—IRAK4—AGE/RAGE pathway—NCF1—intracranial aneurysm	0.0119	0.0204	CbGpPWpGaD
Gefitinib—MKNK2—medulla oblongata—intracranial aneurysm	0.0116	0.0281	CbGeAlD
Gefitinib—CSNK1E—midbrain—intracranial aneurysm	0.0116	0.028	CbGeAlD
Gefitinib—MKNK1—medulla oblongata—intracranial aneurysm	0.0115	0.0278	CbGeAlD
Gefitinib—CHEK2—brain—intracranial aneurysm	0.0115	0.0277	CbGeAlD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—CST3—intracranial aneurysm	0.0112	0.0192	CbGpPWpGaD
Gefitinib—ERBB3—midbrain—intracranial aneurysm	0.0112	0.027	CbGeAlD
Gefitinib—IRAK1—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—AGER—intracranial aneurysm	0.0108	0.0185	CbGpPWpGaD
Gefitinib—MKNK2—midbrain—intracranial aneurysm	0.0106	0.0257	CbGeAlD
Gefitinib—IRAK1—midbrain—intracranial aneurysm	0.0106	0.0257	CbGeAlD
Gefitinib—MKNK1—midbrain—intracranial aneurysm	0.0105	0.0254	CbGeAlD
Gefitinib—EPHA6—brain—intracranial aneurysm	0.0103	0.0249	CbGeAlD
Gefitinib—MAP3K19—brain—intracranial aneurysm	0.00937	0.0226	CbGeAlD
Gefitinib—EGFR—cerebellum—intracranial aneurysm	0.00933	0.0225	CbGeAlD
Gefitinib—CHEK2—FOXM1 transcription factor network—MMP2—intracranial aneurysm	0.00927	0.0158	CbGpPWpGaD
Gefitinib—CSNK1E—cerebellum—intracranial aneurysm	0.00897	0.0217	CbGeAlD
Gefitinib—IRAK4—cerebellum—intracranial aneurysm	0.00883	0.0213	CbGeAlD
Gefitinib—ERBB3—cerebellum—intracranial aneurysm	0.00866	0.0209	CbGeAlD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—CTSS—intracranial aneurysm	0.00859	0.0147	CbGpPWpGaD
Gefitinib—EPHA6—EPH-ephrin mediated repulsion of cells—MMP2—intracranial aneurysm	0.00846	0.0144	CbGpPWpGaD
Gefitinib—MAP2K5—medulla oblongata—intracranial aneurysm	0.00845	0.0204	CbGeAlD
Gefitinib—IRAK1—IL1 and megakaryotyces in obesity—CCL2—intracranial aneurysm	0.00829	0.0141	CbGpPWpGaD
Gefitinib—MKNK2—cerebellum—intracranial aneurysm	0.00823	0.0199	CbGeAlD
Gefitinib—IRAK1—cerebellum—intracranial aneurysm	0.00823	0.0199	CbGeAlD
Gefitinib—MKNK1—cerebellum—intracranial aneurysm	0.00813	0.0196	CbGeAlD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—CTSK—intracranial aneurysm	0.0079	0.0135	CbGpPWpGaD
Gefitinib—IRAK4—AGE/RAGE pathway—AGER—intracranial aneurysm	0.00775	0.0132	CbGpPWpGaD
Gefitinib—MAP2K5—midbrain—intracranial aneurysm	0.00772	0.0187	CbGeAlD
Gefitinib—EGFR—brain—intracranial aneurysm	0.00758	0.0183	CbGeAlD
Gefitinib—CSNK1E—brain—intracranial aneurysm	0.00729	0.0176	CbGeAlD
Gefitinib—IRAK4—brain—intracranial aneurysm	0.00717	0.0173	CbGeAlD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—CST3—intracranial aneurysm	0.00717	0.0122	CbGpPWpGaD
Gefitinib—ERBB3—brain—intracranial aneurysm	0.00703	0.017	CbGeAlD
Gefitinib—STK10—cerebellum—intracranial aneurysm	0.00669	0.0162	CbGeAlD
Gefitinib—MKNK2—brain—intracranial aneurysm	0.00669	0.0161	CbGeAlD
Gefitinib—IRAK1—brain—intracranial aneurysm	0.00669	0.0161	CbGeAlD
Gefitinib—MKNK1—brain—intracranial aneurysm	0.0066	0.0159	CbGeAlD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—CTSB—intracranial aneurysm	0.00654	0.0112	CbGpPWpGaD
Gefitinib—IRAK4—IL-1 signaling pathway—CCL2—intracranial aneurysm	0.00643	0.011	CbGpPWpGaD
Gefitinib—EPHA6—EPH-ephrin mediated repulsion of cells—MMP9—intracranial aneurysm	0.00636	0.0109	CbGpPWpGaD
Gefitinib—IRAK4—MyD88 cascade initiated on plasma membrane—AGER—intracranial aneurysm	0.00633	0.0108	CbGpPWpGaD
Gefitinib—IRAK4—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—AGER—intracranial aneurysm	0.00627	0.0107	CbGpPWpGaD
Gefitinib—IRAK4—MyD88 dependent cascade initiated on endosome—AGER—intracranial aneurysm	0.00616	0.0105	CbGpPWpGaD
Gefitinib—MAP2K5—cerebellum—intracranial aneurysm	0.00598	0.0144	CbGeAlD
Gefitinib—IRAK4—Toll Like Receptor 9 (TLR9) Cascade—AGER—intracranial aneurysm	0.00594	0.0101	CbGpPWpGaD
Gefitinib—IRAK1—IL1 and megakaryotyces in obesity—MMP9—intracranial aneurysm	0.00593	0.0101	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—CST3—intracranial aneurysm	0.0059	0.0101	CbGpPWpGaD
Gefitinib—IRAK4—MyD88:Mal cascade initiated on plasma membrane—AGER—intracranial aneurysm	0.00584	0.00997	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—CTSS—intracranial aneurysm	0.0057	0.00973	CbGpPWpGaD
Gefitinib—STK10—brain—intracranial aneurysm	0.00544	0.0131	CbGeAlD
Gefitinib—EGFR—AGE/RAGE pathway—NCF1—intracranial aneurysm	0.0053	0.00905	CbGpPWpGaD
Gefitinib—MAP2K5—BDNF signaling pathway—NCF1—intracranial aneurysm	0.00529	0.00903	CbGpPWpGaD
Gefitinib—IRAK4—AGE/RAGE pathway—MMP2—intracranial aneurysm	0.00529	0.00903	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—CTSK—intracranial aneurysm	0.00525	0.00895	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—RBBP8—intracranial aneurysm	0.00508	0.00868	CbGpPWpGaD
Gefitinib—IRAK4—Activated TLR4 signalling—AGER—intracranial aneurysm	0.00504	0.0086	CbGpPWpGaD
Gefitinib—IRAK4—AGE/RAGE pathway—NOS3—intracranial aneurysm	0.00495	0.00846	CbGpPWpGaD
Gefitinib—EPHA6—EPH-Ephrin signaling—MMP2—intracranial aneurysm	0.00494	0.00844	CbGpPWpGaD
Gefitinib—MAP2K5—brain—intracranial aneurysm	0.00485	0.0117	CbGeAlD
Gefitinib—IRAK4—Toll Like Receptor 4 (TLR4) Cascade—AGER—intracranial aneurysm	0.00474	0.00809	CbGpPWpGaD
Gefitinib—IRAK1—TRAF6 Mediated Induction of proinflammatory cytokines—AGER—intracranial aneurysm	0.00464	0.00793	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—STARD13—intracranial aneurysm	0.00462	0.00789	CbGpPWpGaD
Gefitinib—MKNK1—Disease—SLC25A16—intracranial aneurysm	0.00458	0.00781	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—RBBP8—intracranial aneurysm	0.00436	0.00744	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—CTSB—intracranial aneurysm	0.00434	0.00741	CbGpPWpGaD
Gefitinib—IRAK1—IL-1 signaling pathway—CCL2—intracranial aneurysm	0.00427	0.00729	CbGpPWpGaD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—AGER—intracranial aneurysm	0.00422	0.00721	CbGpPWpGaD
Gefitinib—IRAK1—MyD88 cascade initiated on plasma membrane—AGER—intracranial aneurysm	0.0042	0.00717	CbGpPWpGaD
Gefitinib—IRAK1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—AGER—intracranial aneurysm	0.00416	0.00711	CbGpPWpGaD
Gefitinib—ABCG2—medulla oblongata—intracranial aneurysm	0.00411	0.00993	CbGeAlD
Gefitinib—IRAK1—MyD88 dependent cascade initiated on endosome—AGER—intracranial aneurysm	0.00409	0.00698	CbGpPWpGaD
Gefitinib—CYP2D6—brainstem—intracranial aneurysm	0.00404	0.00976	CbGeAlD
Gefitinib—IRAK4—AGE/RAGE pathway—MMP9—intracranial aneurysm	0.00397	0.00678	CbGpPWpGaD
Gefitinib—IRAK1—Toll Like Receptor 9 (TLR9) Cascade—AGER—intracranial aneurysm	0.00394	0.00673	CbGpPWpGaD
Gefitinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—AGER—intracranial aneurysm	0.00388	0.00662	CbGpPWpGaD
Gefitinib—ABCG2—midbrain—intracranial aneurysm	0.00376	0.00907	CbGeAlD
Gefitinib—IRAK1—MyD88-independent cascade—AGER—intracranial aneurysm	0.00372	0.00635	CbGpPWpGaD
Gefitinib—EPHA6—EPH-Ephrin signaling—MMP9—intracranial aneurysm	0.00372	0.00634	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—STARD13—intracranial aneurysm	0.0036	0.00614	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—SLC25A16—intracranial aneurysm	0.00356	0.00608	CbGpPWpGaD
Gefitinib—ALB—brain—intracranial aneurysm	0.00346	0.00834	CbGeAlD
Gefitinib—EGFR—AGE/RAGE pathway—AGER—intracranial aneurysm	0.00344	0.00587	CbGpPWpGaD
Gefitinib—IRAK1—Activated TLR4 signalling—AGER—intracranial aneurysm	0.00335	0.00571	CbGpPWpGaD
Gefitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—AGER—intracranial aneurysm	0.00315	0.00537	CbGpPWpGaD
Gefitinib—ABCG2—cerebellum—intracranial aneurysm	0.00291	0.00702	CbGeAlD
Gefitinib—MAP2K5—Signaling Pathways—STARD13—intracranial aneurysm	0.00284	0.00485	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—AGER—intracranial aneurysm	0.0028	0.00478	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CTSS—intracranial aneurysm	0.00278	0.00475	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STARD13—intracranial aneurysm	0.00274	0.00468	CbGpPWpGaD
Gefitinib—ERBB3—Disease—SLC25A16—intracranial aneurysm	0.00271	0.00463	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—CST3—intracranial aneurysm	0.00261	0.00445	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CTSK—intracranial aneurysm	0.00256	0.00437	CbGpPWpGaD
Gefitinib—EGFR—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—intracranial aneurysm	0.00253	0.00432	CbGpPWpGaD
Gefitinib—EGFR—Thromboxane A2 receptor signaling—NOS3—intracranial aneurysm	0.00251	0.00428	CbGpPWpGaD
Gefitinib—EGFR—SHP2 signaling—NOS3—intracranial aneurysm	0.00244	0.00416	CbGpPWpGaD
Gefitinib—ALB—Platelet degranulation—TIMP1—intracranial aneurysm	0.00241	0.00411	CbGpPWpGaD
Gefitinib—EGFR—LPA receptor mediated events—MMP2—intracranial aneurysm	0.00241	0.00411	CbGpPWpGaD
Gefitinib—ABCG2—brain—intracranial aneurysm	0.00236	0.0057	CbGeAlD
Gefitinib—EGFR—AGE/RAGE pathway—MMP2—intracranial aneurysm	0.00235	0.00401	CbGpPWpGaD
Gefitinib—ALB—Response to elevated platelet cytosolic Ca2+—TIMP1—intracranial aneurysm	0.0023	0.00392	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STARD13—intracranial aneurysm	0.00228	0.00389	CbGpPWpGaD
Gefitinib—CYP1A1—brain—intracranial aneurysm	0.00224	0.00541	CbGeAlD
Gefitinib—ERBB3—Innate Immune System—CTSS—intracranial aneurysm	0.00222	0.00379	CbGpPWpGaD
Gefitinib—EGFR—AGE/RAGE pathway—NOS3—intracranial aneurysm	0.0022	0.00375	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CTSS—intracranial aneurysm	0.00213	0.00363	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CTSB—intracranial aneurysm	0.00212	0.00362	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CTSK—intracranial aneurysm	0.00204	0.00348	CbGpPWpGaD
Gefitinib—ABCB1—medulla oblongata—intracranial aneurysm	0.00203	0.0049	CbGeAlD
Gefitinib—MAP2K5—EGF/EGFR Signaling Pathway—NOS3—intracranial aneurysm	0.002	0.00341	CbGpPWpGaD
Gefitinib—CYP2D6—cerebellum—intracranial aneurysm	0.00199	0.00481	CbGeAlD
Gefitinib—ERBB3—Adaptive Immune System—CTSK—intracranial aneurysm	0.00196	0.00335	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—intracranial aneurysm	0.00195	0.00332	CbGpPWpGaD
Gefitinib—ABCB1—midbrain—intracranial aneurysm	0.00185	0.00447	CbGeAlD
Gefitinib—IRAK1—Innate Immune System—CTSS—intracranial aneurysm	0.00185	0.00315	CbGpPWpGaD
Gefitinib—EPHA6—Axon guidance—MMP2—intracranial aneurysm	0.00184	0.00314	CbGpPWpGaD
Gefitinib—EGFR—LPA receptor mediated events—MMP9—intracranial aneurysm	0.00181	0.00309	CbGpPWpGaD
Gefitinib—EGFR—AGE/RAGE pathway—MMP9—intracranial aneurysm	0.00176	0.00301	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CST3—intracranial aneurysm	0.00175	0.00299	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—CCL2—intracranial aneurysm	0.00175	0.00298	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.00173	0.00295	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CTSK—intracranial aneurysm	0.0017	0.0029	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CTSB—intracranial aneurysm	0.00169	0.00288	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CTSB—intracranial aneurysm	0.00162	0.00277	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CTSS—intracranial aneurysm	0.00162	0.00277	CbGpPWpGaD
Gefitinib—CYP2D6—brain—intracranial aneurysm	0.00162	0.00391	CbGeAlD
Gefitinib—ERBB3—Adaptive Immune System—NCF1—intracranial aneurysm	0.00161	0.00275	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—CCL2—intracranial aneurysm	0.00155	0.00265	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STARD13—intracranial aneurysm	0.00153	0.0026	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NCF1—intracranial aneurysm	0.00153	0.0026	CbGpPWpGaD
Gefitinib—EGFR—Disease—SLC25A16—intracranial aneurysm	0.00151	0.00258	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CTSK—intracranial aneurysm	0.00149	0.00254	CbGpPWpGaD
Gefitinib—ABCB1—cerebellum—intracranial aneurysm	0.00143	0.00346	CbGeAlD
Gefitinib—ALB—Folate Metabolism—CCL2—intracranial aneurysm	0.00142	0.00243	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CTSB—intracranial aneurysm	0.00141	0.0024	CbGpPWpGaD
Gefitinib—EPHA6—Axon guidance—MMP9—intracranial aneurysm	0.00138	0.00236	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—AGER—intracranial aneurysm	0.00137	0.00233	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CST3—intracranial aneurysm	0.00136	0.00233	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—intracranial aneurysm	0.00132	0.00224	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—MMP2—intracranial aneurysm	0.00131	0.00224	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CTSS—intracranial aneurysm	0.00129	0.0022	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—MMP2—intracranial aneurysm	0.00129	0.0022	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CTSS—intracranial aneurysm	0.00123	0.00211	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CTSB—intracranial aneurysm	0.00123	0.00211	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NCF1—intracranial aneurysm	0.00123	0.0021	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CTSK—intracranial aneurysm	0.00119	0.00203	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.00119	0.00203	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NCF1—intracranial aneurysm	0.00119	0.00202	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CTSS—intracranial aneurysm	0.00119	0.00202	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—SLC25A16—intracranial aneurysm	0.00118	0.00202	CbGpPWpGaD
Gefitinib—ABCB1—brain—intracranial aneurysm	0.00116	0.00281	CbGeAlD
Gefitinib—EGFR—Innate Immune System—CTSK—intracranial aneurysm	0.00114	0.00194	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—CCL2—intracranial aneurysm	0.00113	0.00193	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—MMP9—intracranial aneurysm	0.00111	0.00189	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CTSK—intracranial aneurysm	0.00109	0.00186	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—AGER—intracranial aneurysm	0.00109	0.00186	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.00108	0.00185	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CTSS—intracranial aneurysm	0.00108	0.00184	CbGpPWpGaD
Gefitinib—EGFR—EGF/EGFR Signaling Pathway—NOS3—intracranial aneurysm	0.00107	0.00183	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—TIMP1—intracranial aneurysm	0.00107	0.00182	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NCF1—intracranial aneurysm	0.00107	0.00182	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CST3—intracranial aneurysm	0.00104	0.00177	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EDNRA—intracranial aneurysm	0.00101	0.00172	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CTSK—intracranial aneurysm	0.00099	0.00169	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—MMP9—intracranial aneurysm	0.000985	0.00168	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CTSB—intracranial aneurysm	0.000984	0.00168	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NCF1—intracranial aneurysm	0.000979	0.00167	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000973	0.00166	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000961	0.00164	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CTSB—intracranial aneurysm	0.00094	0.00161	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—AGER—intracranial aneurysm	0.000908	0.00155	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NCF1—intracranial aneurysm	0.000904	0.00154	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CTSB—intracranial aneurysm	0.000903	0.00154	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NCF1—intracranial aneurysm	0.000898	0.00153	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000887	0.00151	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SLC25A16—intracranial aneurysm	0.000846	0.00144	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NCF1—intracranial aneurysm	0.000831	0.00142	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CTSB—intracranial aneurysm	0.000819	0.0014	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NCF1—intracranial aneurysm	0.000815	0.00139	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SLC25A16—intracranial aneurysm	0.000799	0.00136	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AGER—intracranial aneurysm	0.000797	0.00136	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EDNRA—intracranial aneurysm	0.000784	0.00134	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ASAH1—intracranial aneurysm	0.000782	0.00133	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SLC25A16—intracranial aneurysm	0.000728	0.00124	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTSS—intracranial aneurysm	0.000719	0.00123	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTSK—intracranial aneurysm	0.000662	0.00113	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP2—intracranial aneurysm	0.000657	0.00112	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NCF1—intracranial aneurysm	0.000657	0.00112	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SLC25A16—intracranial aneurysm	0.000654	0.00112	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC25A16—intracranial aneurysm	0.000638	0.00109	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AGER—intracranial aneurysm	0.000635	0.00108	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NCF1—intracranial aneurysm	0.000633	0.00108	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NOS3—intracranial aneurysm	0.000633	0.00108	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EDNRA—intracranial aneurysm	0.00062	0.00106	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AGER—intracranial aneurysm	0.000607	0.00104	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC25A16—intracranial aneurysm	0.000601	0.00103	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EDNRA—intracranial aneurysm	0.000598	0.00102	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC25A16—intracranial aneurysm	0.000596	0.00102	CbGpPWpGaD
Gefitinib—EGFR—Disease—CST3—intracranial aneurysm	0.000579	0.000988	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000563	0.000961	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ASAH1—intracranial aneurysm	0.00056	0.000956	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TIMP1—intracranial aneurysm	0.000551	0.00094	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTSB—intracranial aneurysm	0.000548	0.000935	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NCF1—intracranial aneurysm	0.000545	0.00093	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ASAH1—intracranial aneurysm	0.000529	0.000904	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AGER—intracranial aneurysm	0.000529	0.000903	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NCF1—intracranial aneurysm	0.000527	0.000899	CbGpPWpGaD
Gefitinib—EGFR—Disease—NCF1—intracranial aneurysm	0.000503	0.000859	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000498	0.000849	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCL2—intracranial aneurysm	0.000497	0.000848	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP9—intracranial aneurysm	0.000494	0.000843	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NOS3—intracranial aneurysm	0.000492	0.00084	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ASAH1—intracranial aneurysm	0.000483	0.000824	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP2—intracranial aneurysm	0.000469	0.000801	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NOS3—intracranial aneurysm	0.000443	0.000756	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ASAH1—intracranial aneurysm	0.000433	0.000739	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ASAH1—intracranial aneurysm	0.000423	0.000722	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ASAH1—intracranial aneurysm	0.000398	0.00068	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ASAH1—intracranial aneurysm	0.000395	0.000674	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC25A16—intracranial aneurysm	0.000393	0.000671	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCL2—intracranial aneurysm	0.000387	0.00066	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOS3—intracranial aneurysm	0.000375	0.00064	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—intracranial aneurysm	0.000355	0.000607	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AGER—intracranial aneurysm	0.000354	0.000604	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—intracranial aneurysm	0.000353	0.000602	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NCF1—intracranial aneurysm	0.000352	0.000601	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NOS3—intracranial aneurysm	0.000345	0.000588	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EDNRA—intracranial aneurysm	0.000333	0.000568	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCL2—intracranial aneurysm	0.000306	0.000522	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCL2—intracranial aneurysm	0.000295	0.000503	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCL2—intracranial aneurysm	0.000278	0.000474	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—intracranial aneurysm	0.000276	0.000472	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NOS3—intracranial aneurysm	0.000272	0.000465	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOS3—intracranial aneurysm	0.000263	0.000448	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ASAH1—intracranial aneurysm	0.00026	0.000445	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS3—intracranial aneurysm	0.000248	0.000424	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL2—intracranial aneurysm	0.000245	0.000419	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOS3—intracranial aneurysm	0.000219	0.000373	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—intracranial aneurysm	0.000218	0.000373	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—intracranial aneurysm	0.000211	0.000359	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS3—intracranial aneurysm	0.000209	0.000356	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—intracranial aneurysm	0.000175	0.000299	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—intracranial aneurysm	0.000164	0.00028	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—intracranial aneurysm	0.000163	0.000279	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—intracranial aneurysm	0.000146	0.000249	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—intracranial aneurysm	0.000117	0.0002	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—intracranial aneurysm	0.000117	0.0002	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—intracranial aneurysm	0.00011	0.000189	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—intracranial aneurysm	0.000101	0.000172	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—intracranial aneurysm	9.04e-05	0.000154	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—intracranial aneurysm	8.82e-05	0.000151	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—intracranial aneurysm	8.31e-05	0.000142	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—intracranial aneurysm	8.24e-05	0.000141	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—intracranial aneurysm	5.43e-05	9.28e-05	CbGpPWpGaD
